← All trials

NCT05158140

Phase 3Interventional

Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.

View on ClinicalTrials.gov ↗

Timeline

Start date
Jan 12, 2022
Primary completion
Jan 5, 2023
Completion date
Jan 5, 2023
First posted
Dec 15, 2021
Last posted
Dec 15, 2021
Enrollment
1300
Arms / groups
4 / —
Source
AACT · ingestion pipeline

Sponsors

Drugs studied

Indications studied

CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.